PPARD and prostate cancer: Interestingly, prostatic-epithelial-targeted genetic deletion of PPAR-δ’s DNA binding domain [7] has been recently reported to increase cellularity; in this setting, PPAR-δ was proposed to suppress prostate cancer via DNA-binding-dependent but ligand-binding-independent mechanisms [78].